Drug Safety

, Volume 24, Issue 7, pp 483–490 | Cite as

Drug-Induced Liver Disorders

Implications for Drug Development and Regulation
  • Neil KaplowitzEmail author
Current Opinion


Drug-induced hepatotoxicity is a frequent cause of liver disease. Although often presenting as acute hepatitis and/or cholestasis, virtually any clinicalpathological pattern of acute or chronic liver disease can occur. Most reactions occur in a small proportion of the population using a particular drug. Each drug associated with hepatotoxicity tends to have a characteristic signature regarding latency and pattern of injury. The mechanism can be drug metabolism-dependent or related to the chemical properties of the parent drug. The former are immune mediated or due to metabolic idiosyncrasy. Monitoring serum ALT levels is of unproven effectiveness but should be considered when there is an increased risk of delayed onset serious hepatitis-like reactions. The key for the future is improved identification of toxic potential in preclinical studies, clinical trials and postmarketing experience. The elucidation of the genetic and environmental mechanisms contributing to delayed idiosyncratic reactions is a major barrier to overcome in this field.


Nimesulide Troglitazone Acute Liver Failure Idiosyncratic Reaction Overt Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Ostapowicz G, Fontana RB, Larson AM, et al. Etiology and outcome of acute liver failure in the USA: preliminary results of a prospective multi-center study [abstract]. Hepatology 1999; 30(4): 221AGoogle Scholar
  2. 2.
    Shakil A, Kramer D, Mazariegos G, et al. Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl 2000; 16: 163–9Google Scholar
  3. 3.
    Zimmerman H. Drug-induced liver disease, In: Schiff E, Sorrell M and Maddrey W, editors. Schiff’s diseases of the liver. 8th ed. Philadelphia (PA): Lippincott-Raven Publishers, 1999: 973–1064Google Scholar
  4. 4.
    Kaplowitz N. Drug metabolism and hepatotoxicity. In: Kaplowitz N, editor. Liver and biliary diseases. 2nd ed. Baltimore (MD): Williams and Wilkins, 1996: 103–20Google Scholar
  5. 5.
    Desmet VJ. Vanishing bile duct syndrome in drug-induced liver disease. J Hepatology 1997; 26Suppl. 1: 31–5CrossRefGoogle Scholar
  6. 6.
    Degott C, Feldmann G, Larrey D, et al. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology 1992; 15: 244–51PubMedCrossRefGoogle Scholar
  7. 7.
    Van Steenberen W, Peeters P, DeBondt J, et al. Nimesulideinduced acute hepatitis: evidence from six cases. J Hepatology 1998; 29: 135–41CrossRefGoogle Scholar
  8. 8.
    Pham T-V, Lu S, Kaplowitz N. Acetaminophen hepatotoxicity. In: Taylor, editor. Gastrointestinal emergencies. 2nd ed. Baltimore (MD): Williams & Wilkins, 1997: 371–88Google Scholar
  9. 9.
    Tarazi E, Harter JG, Zimmerman HJ, et al. Sulindac-associated hepatic injury: analysis of 91 cases reported to the Food and Drug Administration. Gastroenterology 1993; 104: 569–74PubMedGoogle Scholar
  10. 10.
    Shear N, Spielberg S. Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest 1988; 82: 1826–32PubMedCrossRefGoogle Scholar
  11. 11.
    Larrey D, Vial T, Micaleff A, et al. Hepatitis associated with amoxycillin-clavulanic acid combination. Report of 15 cases Gut. 1992; 33: 368–71Google Scholar
  12. 12.
    Thompson N, Caplin M, Hamilton M, et al. Anti-tuberculosis medication and the liver: dangers and recommendations in management. Eur Respir J 1995; 8: 1384–8PubMedCrossRefGoogle Scholar
  13. 13.
    Murphy E, Davern T, Shakil O, et al. Troglitazone-induced fulminant hepatic failure. Dig Dis Sci 2000; 45: 549–3PubMedCrossRefGoogle Scholar
  14. 14.
    Durand F, Bernuau J, Pessayre D, et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculosis treatment including isoniazid. Hepatology 1995; 21: 929–32PubMedCrossRefGoogle Scholar
  15. 15.
    Rieder M, Uetrecht J, Shear N, et al. Diagnosis of sulfonamide hypersensitivity reactions by in vitro ‘rechallenge’ with hydroxylamine metabolites. Ann Int Med 1989; 110: 286–9PubMedGoogle Scholar
  16. 16.
    Rieder M, Shear N, Kanee A, et al. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991; 49: 13–7PubMedCrossRefGoogle Scholar
  17. 17.
    Gennis M, Vemusi R, Burns E, et al. Familial occurrence of hypersensitivity to phenytoin. Am J Med 1991; 91: 631–4PubMedCrossRefGoogle Scholar
  18. 18.
    Robin M, LeRoy M, Descatoire V, et al. Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J Hepatol 1997; 26(1): 23–30PubMedCrossRefGoogle Scholar
  19. 19.
    Berson A, DeBeco V, Letteron P, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 1998; 114: 764–4PubMedCrossRefGoogle Scholar
  20. 20.
    Brinkman K, Hofstede H, Burger D, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12: 1735–44PubMedCrossRefGoogle Scholar
  21. 21.
    Kowdley K, Keeffe E. Hepatotoxicity of transplant immunosuppressive agents. Gastroenterol Clin North Am 1995; 24: 991–1001PubMedGoogle Scholar
  22. 22.
    DeLeve L, Kaplowitz N. Prevention and therapy of druginduced hepatic injury. In: Wolfe MM, editor. Therapy of digestive disorders. Philadelphia (PA): W.B. Saunders, Harcourt Brace & Company, 2000: 334–48Google Scholar
  23. 23.
    Zimmerman H, Maddrey W. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 1995; 22: 767–3PubMedCrossRefGoogle Scholar
  24. 24.
    Makin A, Williams R. Paracetamol hepatotoxicity and alcohol consumption in deliberate and accidental overdose. Q J Med 2000; 93: 341–9CrossRefGoogle Scholar
  25. 25.
    Moses P, Schroeder B, Alkhatib O, et al. Severe hepatotoxicity associated with bromfenac sodium. Am J Gastroenterol 1999; 94: 1393–6PubMedCrossRefGoogle Scholar
  26. 26.
    Watkins P, Whitcomb R. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338: 916–7PubMedCrossRefGoogle Scholar
  27. 27.
    Beaune P, Lecoeur S. Immunotoxicology of the liver: adverse reactions to drugs. J Hepatol 1997; 26Suppl. 2: 37–42PubMedCrossRefGoogle Scholar
  28. 28.
    Neuberger J. Immune mechanisms in drug hepatotoxicity. Cli Liver Dis 1998; 2: 471–82CrossRefGoogle Scholar
  29. 29.
    Maria V, Victorino R. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26: 664–9PubMedCrossRefGoogle Scholar
  30. 30.
    Benichou C. Criteria of drug induced liver disorders: Report of an international consensus meeting. J Hepatol 1990; 11: 272–6PubMedCrossRefGoogle Scholar
  31. 31.
    Danan G, Benichou C. Causality assessment of adverse reactions to drugs - I: a novel method based on the conclusions of international consensus meetings: application to druginduced liver injuries. J Clin Epidemiol 1993; 46: 1323–30PubMedCrossRefGoogle Scholar
  32. 32.
    Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs - II: an original model or validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46: 1331–6PubMedCrossRefGoogle Scholar
  33. 33.
    Lucena M, Camargo R, Andrade R, et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001; 33: 123–30PubMedCrossRefGoogle Scholar
  34. 34.
    Kaplowitz N. Causality assessment versus guilt by association in drug hepatotoxicity. Hepatology 2001; 33: 308–10PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.GI/Liver Division, USC Research Center for Liver Diseases, Keck School of MedicineUniversity of Southern CaliforniaLos AngelesUSA

Personalised recommendations